Both Orphenadrine and Strattera offer similar effectiveness in symptom control, with the main difference being how quickly they act. Either drug is a viable option depending on the patient’s needs.

Both Orphenadrine and Strattera have similar safety profiles, with mild and transient side effects. Neither presents significant long-term safety concerns.

Both Orphenadrine and Strattera have a low risk of addiction when used correctly under medical supervision, with minimal potential for misuse.

Strattera offers greater flexibility with different delivery forms, making it suitable for patients with specific preferences or medical needs.

Both Orphenadrine and Strattera have some contraindications based on individual health conditions, but neither has significantly more restrictions than the other.

Strattera is better suited for chronic conditions, offering longer-lasting effects and a favorable safety profile for long-term use. Its flexibility in administration makes it a strong option for various patient needs.